AUG 28, 2020 9:19 AM PDT

Using CRISPR-Cas12a to Repair Hereditary Cancers in the Lab

WRITTEN BY: Jasper Cantrell

Genome repair is one of the big-ticket research areas for the future of medicine. CRISPR-Cas9 systems can edit the genome in the lab, but a new study from Fukushima Medical University in Japan shows that Cas12a, not Cas 9, may prove to be a better tool for the future of the field.

The use of CRISPR systems in gene editing was a breakthrough many had been waiting for. Engineered from a bacterial defense mechanism against viruses, this system is used to target a specific genome location and edit it. Unfortunately, many current CRISPR systems suffer from issues like leaving scars or not being accurate enough. This new study sought to use the CRISPER-Cas12a system to repair point mutations in multiple endocrine neoplasia type 2B (MEN2B) and dystrophic epidermolysis bullosa (DEB).

The main differences between Cas9 and Cas12a are in Cas12a’s target recognition and DNA cutting method. Cas12a leaves “overhangs” when it cuts the DNA, while Cas9 leaves “blunt ends.” Blunt ends are much harder to repair, while overhangs are much easier and quicker. Cas12a also has improved target recognition, which improves the speed and accuracy of the system.

The team’s goal was to use this system to target and repair the single nucleotide mutations in both MEN2B and DEB. MEN2B, a type of inherited cancer, is characterized by a single mutation (M918T) in the RET gene, while DEB by a mutation in the COL7A1 gene. The team would design a targeted CRISPR-Cas12a that would replace the area with the point mutation with the correct DNA. The repaired sequence would have a harmless marker mutation so that the team could confirm it worked.

This system successfully produced a scarless repair to both disease models, with fewer steps than its closest competitor. The team did note that there were false positives with their marker system but used several types of testing to ensure their data accuracy.

They termed this CRISPR-Cas12a method “One-SHOT,” for its ability to target single mutations. The study supported its superior speed and efficiency in scarless repairs compared to its competitors. One should note that the repair rate was fairly low at 1%-7.5%, but the team still achieved its primary objective of creating a precise and accurate gene-editing method.

The study concludes, “The One-SHOT procedure developed in this study is simple, fast, low-cost, efficient, and broadly applicable to genome-editing applications in basic biological and biomedical research. We anticipate that One- SHOT will become a powerful procedure for generating isogenic cells from disease-specific iPSCs and for repairing genomic mutations in somatic cells, germ-line stem cells, and iPSCs.”

Sources: Nature Scientific Reports, Integrated DNA Technologies

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 07, 2020
Cancer
How Down Syndrome genes safeguard against solid tumors
AUG 07, 2020
How Down Syndrome genes safeguard against solid tumors
Are people with Down syndrome protected from developing solid tumors in some way? So suggests new research published in ...
AUG 09, 2020
Cancer
Reducing post-surgery metastasis in colorectal cancer patients
AUG 09, 2020
Reducing post-surgery metastasis in colorectal cancer patients
Scientists have recently shown the successful reduction of metastasis in post-surgery colorectal cancer patients. The st ...
SEP 12, 2020
Cancer
Treating cancer with the botanical andrographis
SEP 12, 2020
Treating cancer with the botanical andrographis
A study from City of Hope published in the journal Carcinogenesis reports that the use of the natural botanical And ...
SEP 13, 2020
Cancer
Should we be treating kidney cancer differently?
SEP 13, 2020
Should we be treating kidney cancer differently?
New research published in the journal Clinical Cancer Research is questioning how we treat kidney tumors. According ...
SEP 22, 2020
Cardiology
Investigating the Mechanism Behind 5-Fluorouracil's Cardiotoxicity
SEP 22, 2020
Investigating the Mechanism Behind 5-Fluorouracil's Cardiotoxicity
Cancer therapies have come quite far, with several options available for many cancers. An issue that has plagued many of ...
OCT 09, 2020
Cancer
Cloud technology cuts improve efficiency for cancer nurses
OCT 09, 2020
Cloud technology cuts improve efficiency for cancer nurses
In a new study reported in Clinical Cancer Informatics, an American Society of Clinical Oncology journal, medical provid ...
Loading Comments...